Skip to main content
BD Market Insights Logo
Pharmaceuticals & Healthcare Verified Business Profile

Incepta Pharmaceuticals Ltd.

Leading research-driven pharmaceutical and biotechnology manufacturer in Bangladesh, pioneering domestic vaccine production, monoclonal antibodies, and sterile injectables.

Visit Official Website
Headquarters
Tejgaon Industrial Area, Dhaka, Bangladesh
Primary Sector
Pharmaceuticals & Healthcare
Established
1999
Editorial Status
Verified Documented

Manufactured Products & Services

Human Vaccines (Rabies, Hepatitis B, Tetanus, Typhoid) Biosimilars & Monoclonal Antibodies Sterile Lyophilized Vials & Pre-Filled Syringes Complex Extended-Release Solid Dosages

Sectors & Client Industries

Biotechnology & Human Vaccines Pharmaceutical Formulations Global Tender & UNICEF Supply

Corporate Overview

Incepta Pharmaceuticals Ltd. is the second-largest pharmaceutical formulation firm in Bangladesh by domestic market share, recognized as the nation’s foremost pioneer in advanced biotherapeutics and vaccine technology. Founded in 1999 by industrialist Abdul Muktadir, Incepta introduced rapid technological modernizations that altered generic drug availability in the region.

Headquartered in Tejgaon, Dhaka, Incepta operates two massive manufacturing sites: the Dhaka Plant in Savar and the Zirabo Formulation Campus in Ashulia.

Vaccine & Biotechnology Manufacturing

Incepta is the only pharmaceutical company in Bangladesh with a full-scale commercial human vaccine manufacturing plant:

  1. Vaccine Division (Zirabo): Dedicated cleanrooms producing essential antigens including Rabies, Cholera, Hepatitis B, Tetanus, and Typhoid vaccines, reducing national reliance on multinational imports.
  2. Monoclonal Antibodies & Biosimilars: Proprietary mammalian cell culture suites producing filgrastim, pegfilgrastim, and erythropoietin for oncology and nephrology therapies.
  3. High-Speed Lyophilization: Advanced German freeze-drying systems for sterile injectable powders supplied to UNICEF and international healthcare tenders.

Research & Development Footprint

Incepta’s R&D center employs over 400 specialized scientists focused on reverse engineering complex multi-particulate drug delivery systems, nano-emulsions, and sustained-release pellets.

Sources, Data & References

In accordance with BD Market Insights Editorial Standards, all factual claims, market sizes, and corporate data cited in this publication are cross-referenced with official filings, regulatory bodies, and industry documentation.

  1. Directorate General of Drug Administration (DGDA) Licensing Records — dgda.gov.bd (Accessed: September 28, 2026)
  2. Incepta Pharmaceuticals Corporate Overview — inceptapharma.com (Accessed: September 28, 2026)

Entity Verification Policy

BD Market Insights publishes verified corporate profiles derived from public regulatory filings, direct corporate statements, and established industry documentation. We do not accept paid compensation for profile placement or rankings.

Read our selection criteria →